HOME >> BIOLOGY >> NEWS
Low dose vitamin A derivative does not prevent head and neck tumors, clinical trial finds

Taking a vitamin A derivative called isotretinoin did not reduce the risk of second primary tumors or improve survival in patients with stage I or II head and neck squamous cell cancers (HNSCC), according to a study in the April 5 issue of the Journal of the National Cancer Institute. In addition, current smokers had an increased risk of second primary cancers and death.

HNSCCs are the fifth most common cancers and sixth leading cause of cancer related death today. In 2002, there were 600,000 new cases diagnosed worldwide. Some studies have suggested that vitamin A derivatives called retinoids may halt or even reverse growth of head and neck tumors. A clinical trial of high doses of a retinoid called isotretinoin, widely used to treat cystic acne, in patients with HNSCC found that those receiving isotretinoin developed fewer second primary tumors, particularly smoking-related tumors. However, there were substantial side effects among those who received the high-dose isotretinoin, and subsequent studies of the compound have shown mixed results.

To assess the effect of lower, more tolerable doses of isotretinoin on the development of second primary tumors and survival among patients with early-stage HNSCC, Fadlo R. Khuri, M.D., of the Emory University School of Medicine in Atlanta, and colleagues conducted a randomized clinical trial of 1190 patients diagnosed with stage I or II HNSCC. Patients were randomly assigned to receive low-dose isotretinoin (30 mg/day) or a placebo for 3 years. They continued to monitor the patients for 4 or more years after treatment. This clinical trial is the largest chemoprevention study to date to examine the use of retinoids in patients with early-stage HNSCC.

The study found that low-dose isotretinoin did not reduce the rate of second primary tumors or improve overall survival compared with a placebo. Current smokers in both the treatment and placebo groups had an increased rate of second primary tu
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
4-Apr-2006


Page: 1 2

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Lack of sun does not explain low vitamin D in elderly who are overweight
3. Dietary vitamin B6, B12 and folate, may decrease pancreatic cancer risk among lean people
4. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
5. Heavy multivitamin use may be linked to advanced prostate cancer
6. MIT biologists solve vitamin puzzle
7. High levels of vitamin D in the body may decrease the risk of multiple sclerosis
8. Einstein researchers discover how a key dietary vitamin is absorbed
9. Poor athletic performance linked to vitamin deficiency
10. Super chow, laced with semi-synthetic vitamin E derivative, inhibited spread of cancer in mice
11. Prenatal vitamins may reduce risk of brain tumors in children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/4/2019)... , ... April 02, 2019 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... takes place at the Gaylord National Harbor Hotel, Oxon Hill, Maryland, on April ...
(Date:4/4/2019)... ... April 03, 2019 , ... R3 Stem Cell is now ... Centers of Excellence. R3 wants patients to feel secure when they make a ... from Centers that use inferior regenerative biologics, protocols or amounts, R3 provides a ...
(Date:3/29/2019)... ... March 28, 2019 , ... In the wake of ... entirely dedicated to Chinese biobanks was launched in July 2018, in an agreement ... Biobank Branch, China Medicinal Biotech Association (BBCMBA). The one-year pilot programme offered two ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... April 09, 2019 , ... Sonny Bar Lisa, or Sonny ... for approximately two months. After a series of diagnostics, an MRI was performed ... owner, Alison, researched the injury and found that VetStem Regenerative Cell Therapy ...
(Date:4/8/2019)... (PRWEB) , ... April 09, 2019 , ... ... disease, the innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has chosen ... of antibody repertoires is part of CZ Biohub’s efforts to establish new approaches ...
(Date:3/27/2019)... ... March 26, 2019 , ... A leader in the field ... to veterinarians across the United States and Canada since 2004. The primary indications ... tissue injuries in the dog, cat, and horse. Recently, VetStem teamed up ...
(Date:3/23/2019)... ... March 22, 2019 , ... ... LenS3 Multi-Angle Light Scattering (MALS) detector , offering a revolutionary approach for the ... polysaccharides, proteins, and biopolymers. A novel optical design, a unique cell-block assembly, and ...
Breaking Biology Technology:
Cached News: